1. Home
  2. RFL vs ANL Comparison

RFL vs ANL Comparison

Compare RFL & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rafael Holdings Inc. Class B

RFL

Rafael Holdings Inc. Class B

HOLD

Current Price

$1.38

Market Cap

61.1M

Sector

Finance

ML Signal

HOLD

Logo Adlai Nortye Ltd.

ANL

Adlai Nortye Ltd.

HOLD

Current Price

$7.83

Market Cap

293.4M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
RFL
ANL
Founded
2017
2004
Country
United States
Cayman Islands
Employees
N/A
N/A
Industry
Real Estate
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
61.1M
293.4M
IPO Year
2017
2022

Fundamental Metrics

Financial Performance
Metric
RFL
ANL
Price
$1.38
$7.83
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$16.00
AVG Volume (30 Days)
103.5K
210.3K
Earning Date
03-30-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
28.28
N/A
EPS
N/A
N/A
Revenue
$917,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
43.96
N/A
52 Week Low
$1.12
$0.88
52 Week High
$3.19
$12.09

Technical Indicators

Market Signals
Indicator
RFL
ANL
Relative Strength Index (RSI) 52.39 46.82
Support Level $1.35 $7.21
Resistance Level $1.38 $9.98
Average True Range (ATR) 0.12 1.07
MACD -0.01 -0.31
Stochastic Oscillator 32.73 24.49

Price Performance

Historical Comparison
RFL
ANL

About RFL Rafael Holdings Inc. Class B

Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.

About ANL Adlai Nortye Ltd.

Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.

Share on Social Networks: